Selected research
Industry Research
Targeted Protein Degradation Platform Industry Research Report 2026
Market perspective
The global Targeted Protein Degradation Platform market was valued at US$ million in 2025 and is projected to reach US$ million by 2032, implying a CAGR of % over 2026–2032.
North America: the Targeted Protein Degradation Platform market is projected to increase from US$ million in 2026 to US$ million by 2032, reflecting a CAGR of % over 2026–2032. Europe: the Targeted Protein Degradation Platform market is projected to rise from US$ million in 2026 to US$ million by 2032, registering a CAGR of % over 2026–2032. Asia Pacific: the Targeted Protein Degradation Platform market is expected to grow from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026–2032. Leading global service providers of Targeted Protein Degradation Platform include Arvinas, Kymera Therapeutics, Plexium, Nurix, Amphista, Cullgen, Hengrui Pharmaceuticals, Hinova Pharmaceuticals and Ranok Therapeutics. among others; in 2025, the top three vendors together accounted for approximately % of global revenue.
Report Scope
Read the full market overview
This report quantifies the global Targeted Protein Degradation Platform market in terms of revenue (US$ million) and, where applicable, service volume (k units), using 2024 as the base year and providing annual historical and forecast data for 2021–2032.
It standardizes definitions of service Types and end-use Applications, harmonizes provider attribution, and delivers comparable time series by company, Type, Application, and region or country, including indicative price bands (US$/k units) and concentration ratios (CR5/CR10). Outputs are intended to support service design, budgeting, capacity planning, and benchmarking for providers, platforms, channel partners, and investors; the report also reviews technology shifts and notable service innovations relevant to Targeted Protein Degradation Platform.
Key Companies & Market Share Insights
This section profiles leading service providers with 2021–2025 results and a 2026–2032 outlook—covering revenue, market share, price bands, service portfolio and client mix, regional and channel mix, and key developments (M&A, network expansion, certifications). It also provides global revenue, average price, and—where applicable—volume metrics by provider, and calculates CR5/CR10 and rank changes to support comparative benchmarking.
Targeted Protein Degradation Platform Market by Company
Arvinas
Kymera Therapeutics
Plexium
Nurix
Amphista
Cullgen
Hengrui Pharmaceuticals
Hinova Pharmaceuticals
Ranok Therapeutics
Targeted Protein Degradation Platform Segment by Type
PROTAC Platform
Dual-platform (Molecular Glue and PROTAC)
Targeted Protein Degradation Platform Segment by Application
Cancer
Autoimmune Diseases
Other
Targeted Protein Degradation Platform Segment by Region
North America
United States
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Spain
Russia
Netherlands
Nordic Countries
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Southeast Asia
South America
Brazil
Argentina
Chile
Colombia
Middle East & Africa
Saudi Arabia
Israel
United Arab Emirates
Turkey
Iran
Egypt
Key Drivers & Barriers
High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.
Reasons to Buy This Report
1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Targeted Protein Degradation Platform market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Targeted Protein Degradation Platform and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market
5. This report helps stakeholders to gain insights into which regions to target globally
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Targeted Protein Degradation Platform.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.
Chapter Outline
Chapter 1: Research objectives, research methods, data sources, data cross-validation;
Chapter 2: Introduces the report scope of the report, executive summary of different market segments (product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 3: Provides the analysis of various market segments product types, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 4: Provides the analysis of various market segments application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 5: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 6: Detailed analysis of Targeted Protein Degradation Platform companies’ competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 7, 8, 9, 10, 11: North America, Europe, Asia Pacific, South America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 12: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including revenue, gross margin, product introduction, recent development, etc.
Chapter 13: The main points and conclusions of the report.
More report detail
Tables and figures
Scope & coverage.
Types
- PROTAC Platform
- Dual-platform (Molecular Glue and PROTAC)
Applications
- Cancer
- Autoimmune Diseases
- Other
Companies covered
- Arvinas
- Kymera Therapeutics
- Plexium
- Nurix
- Amphista
- Cullgen
- Hengrui Pharmaceuticals
- Hinova Pharmaceuticals
- Ranok Therapeutics
Inside the report.
1 Preface
- 1.1 Scope of Report
- 1.2 Reasons for Doing This Study
- 1.3 Research Methodology
- 1.4 Research Process
- 1.5 Data Source
- 1.5.1 Secondary Sources
- 1.5.2 Primary Sources
2 Market Overview
- 2.1 Product Definition
- 2.2 Targeted Protein Degradation Platform by Type
- 2.2.1 Market Value Comparison by Type (2021 VS 2025 VS 2032)
- 2.2.2 PROTAC Platform
- 2.2.3 Dual-platform (Molecular Glue and PROTAC)
- 2.3 Targeted Protein Degradation Platform by Application
- 2.3.1 Market Value Comparison by Application (2021 VS 2025 VS 2032)
- 2.3.2 Cancer
- 2.3.3 Autoimmune Diseases
- 2.3.4 Other
- 2.4 Assumptions and Limitations
3 Targeted Protein Degradation Platform Breakdown Data by Type
- 3.1 Global Targeted Protein Degradation Platform Historic Market Size by Type (2021-2026)
- 3.2 Global Targeted Protein Degradation Platform Forecasted Market Size by Type (2027-2032)
4 Targeted Protein Degradation Platform Breakdown Data by Application
- 4.1 Global Targeted Protein Degradation Platform Historic Market Size by Application (2021-2026)
- 4.2 Global Targeted Protein Degradation Platform Forecasted Market Size by Application (2027-2032)
5 Global Growth Trends
- 5.1 Global Targeted Protein Degradation Platform Market Perspective (2021-2032)
- 5.2 Global Targeted Protein Degradation Platform Growth Trends by Region
- 5.2.1 Global Targeted Protein Degradation Platform Market Size by Region: 2021 VS 2025 VS 2032
- 5.2.2 Targeted Protein Degradation Platform Historic Market Size by Region (2021-2026)
- 5.2.3 Targeted Protein Degradation Platform Forecasted Market Size by Region (2027-2032)
- 5.3 Targeted Protein Degradation Platform Market Dynamics
- 5.3.1 Targeted Protein Degradation Platform Industry Trends
- 5.3.2 Targeted Protein Degradation Platform Market Drivers
- 5.3.3 Targeted Protein Degradation Platform Market Challenges
- 5.3.4 Targeted Protein Degradation Platform Market Restraints
6 Market Competitive Landscape by Players
- 6.1 Global Top Targeted Protein Degradation Platform Players by Revenue
- 6.1.1 Global Top Targeted Protein Degradation Platform Players by Revenue (2021-2026)
- 6.1.2 Global Targeted Protein Degradation Platform Revenue Market Share by Players (2021-2026)
- 6.2 Global Targeted Protein Degradation Platform Industry Players Ranking, 2023 VS 2024 VS 2025
- 6.3 Global Key Players of Targeted Protein Degradation Platform Head Office and Area Served
- 6.4 Global Targeted Protein Degradation Platform Players, Product Type & Application
- 6.5 Global Targeted Protein Degradation Platform Manufacturers Established Date
- 6.6 Global Targeted Protein Degradation Platform Market CR5 and HHI
- 6.7 Global Players Mergers & Acquisition
7 North America
- 7.1 North America Targeted Protein Degradation Platform Market Size (2021-2032)
- 7.2 North America Targeted Protein Degradation Platform Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 7.3 North America Targeted Protein Degradation Platform Market Size by Country (2021-2026)
- 7.4 North America Targeted Protein Degradation Platform Market Size by Country (2027-2032)
- 7.5 United States
- 7.5 United States
- 7.6 Canada
- 7.7 Mexico
8 Europe
- 8.1 Europe Targeted Protein Degradation Platform Market Size (2021-2032)
- 8.2 Europe Targeted Protein Degradation Platform Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 8.3 Europe Targeted Protein Degradation Platform Market Size by Country (2021-2026)
- 8.4 Europe Targeted Protein Degradation Platform Market Size by Country (2027-2032)
- 8.5 Germany
- 8.6 France
- 8.7 U.K.
- 8.8 Italy
- 8.9 Spain
- 8.10 Russia
- 8.11 Netherlands
- 8.12 Nordic Countries
9 Asia-Pacific
- 9.1 Asia-Pacific Targeted Protein Degradation Platform Market Size (2021-2032)
- 9.2 Asia-Pacific Targeted Protein Degradation Platform Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 9.3 Asia-Pacific Targeted Protein Degradation Platform Market Size by Country (2021-2026)
- 9.4 Asia-Pacific Targeted Protein Degradation Platform Market Size by Country (2027-2032)
- 9.5 China
- 9.6 Japan
- 9.7 South Korea
- 9.8 India
- 9.9 Australia
- 9.10 China Taiwan
- 9.11 Southeast Asia
10 South America
- 10.1 South America Targeted Protein Degradation Platform Market Size (2021-2032)
- 10.2 South America Targeted Protein Degradation Platform Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 10.3 South America Targeted Protein Degradation Platform Market Size by Country (2021-2026)
- 10.4 South America Targeted Protein Degradation Platform Market Size by Country (2027-2032)
- 10.5 Brazil
- 10.6 Argentina
- 10.7 Chile
- 10.8 Colombia
- 10.9 Peru
11 Middle East & Africa
- 11.1 Middle East & Africa Targeted Protein Degradation Platform Market Size (2021-2032)
- 11.2 Middle East & Africa Targeted Protein Degradation Platform Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 11.3 Middle East & Africa Targeted Protein Degradation Platform Market Size by Country (2021-2026)
- 11.4 Middle East & Africa Targeted Protein Degradation Platform Market Size by Country (2027-2032)
- 11.5 Saudi Arabia
- 11.6 Israel
- 11.7 United Arab Emirates
- 11.8 Turkey
- 11.9 Iran
- 11.10 Egypt
12 Players Profiled
- 12.1 Arvinas
- 12.1.1 Arvinas Company Information
- 12.1.2 Arvinas Business Overview
- 12.1.3 Arvinas Revenue in Targeted Protein Degradation Platform Business (2021-2026)
- 12.1.4 Arvinas Targeted Protein Degradation Platform Product Portfolio
- 12.1.5 Arvinas Recent Developments
- 12.2 Kymera Therapeutics
- 12.2.1 Kymera Therapeutics Company Information
- 12.2.2 Kymera Therapeutics Business Overview
- 12.2.3 Kymera Therapeutics Revenue in Targeted Protein Degradation Platform Business (2021-2026)
- 12.2.4 Kymera Therapeutics Targeted Protein Degradation Platform Product Portfolio
- 12.2.5 Kymera Therapeutics Recent Developments
- 12.3 Plexium
- 12.3.1 Plexium Company Information
- 12.3.2 Plexium Business Overview
- 12.3.3 Plexium Revenue in Targeted Protein Degradation Platform Business (2021-2026)
- 12.3.4 Plexium Targeted Protein Degradation Platform Product Portfolio
- 12.3.5 Plexium Recent Developments
- 12.4 Nurix
- 12.4.1 Nurix Company Information
- 12.4.2 Nurix Business Overview
- 12.4.3 Nurix Revenue in Targeted Protein Degradation Platform Business (2021-2026)
- 12.4.4 Nurix Targeted Protein Degradation Platform Product Portfolio
- 12.4.5 Nurix Recent Developments
- 12.5 Amphista
- 12.5.1 Amphista Company Information
- 12.5.2 Amphista Business Overview
- 12.5.3 Amphista Revenue in Targeted Protein Degradation Platform Business (2021-2026)
- 12.5.4 Amphista Targeted Protein Degradation Platform Product Portfolio
- 12.5.5 Amphista Recent Developments
- 12.6 Cullgen
- 12.6.1 Cullgen Company Information
- 12.6.2 Cullgen Business Overview
- 12.6.3 Cullgen Revenue in Targeted Protein Degradation Platform Business (2021-2026)
- 12.6.4 Cullgen Targeted Protein Degradation Platform Product Portfolio
- 12.6.5 Cullgen Recent Developments
- 12.7 Hengrui Pharmaceuticals
- 12.7.1 Hengrui Pharmaceuticals Company Information
- 12.7.2 Hengrui Pharmaceuticals Business Overview
- 12.7.3 Hengrui Pharmaceuticals Revenue in Targeted Protein Degradation Platform Business (2021-2026)
- 12.7.4 Hengrui Pharmaceuticals Targeted Protein Degradation Platform Product Portfolio
- 12.7.5 Hengrui Pharmaceuticals Recent Developments
- 12.8 Hinova Pharmaceuticals
- 12.8.1 Hinova Pharmaceuticals Company Information
- 12.8.2 Hinova Pharmaceuticals Business Overview
- 12.8.3 Hinova Pharmaceuticals Revenue in Targeted Protein Degradation Platform Business (2021-2026)
- 12.8.4 Hinova Pharmaceuticals Targeted Protein Degradation Platform Product Portfolio
- 12.8.5 Hinova Pharmaceuticals Recent Developments
- 12.9 Ranok Therapeutics
- 12.9.1 Ranok Therapeutics Company Information
- 12.9.2 Ranok Therapeutics Business Overview
- 12.9.3 Ranok Therapeutics Revenue in Targeted Protein Degradation Platform Business (2021-2026)
- 12.9.4 Ranok Therapeutics Targeted Protein Degradation Platform Product Portfolio
- 12.9.5 Ranok Therapeutics Recent Developments
13 Report Conclusion
14 Disclaimer
GET THE RESEARCH
Choose your license.
Choose who needs access.
All options are for this report and research series.
PDF by email within 3–5 working days after payment confirmation.
Talk to an analyst